Assessment of Effect of Rapastinel on Driving Performance
Study Identifier
RAP-PK-18
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
21 - 65 Years
Protocol Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.
Study Locations
Location
Status
Location
Collaborative Neuroscience Network
San Clemente, California, United States, 92673
Status
Not applicable
Location
Algorithme Pharma
Aurora, Ontario, Canada, L4G 0A5
Status
Not applicable